Developer docs
API playgroundTry for free, no card

Search company profiles

n-Lorem Foundation

Full company profile

uuid00029rr

Namestring
n-Lorem Foundation
Legal namestring
n-Lorem Foundation
Websiteurl
nlorem.org
Company typeenum
Private
Founded yearint
2020
Descriptiontext

n-Lorem Foundation is a 501(c)(3) nonprofit founded in January 2020 by Dr. Stanley Crooke — the founder of Ionis Pharmaceuticals and creator of antisense oligonucleotide (ASO) technology — to develop and provide personalized experimental ASO medicines to nano-rare disease patients (defined as 1-30 patients worldwide sharing a single pathogenic mutation) for free, for life. The foundation is the only organization worldwide operating at scale on individualized ASOs, with 50+ patients treated, 260+ doses administered, 40+ INDs filed across five FDA divisions plus one CTA with Health Canada, and over 45 patient-years of cumulative safety experience as of April 2026.

The core product is a personalized experimental ASO medicine engineered per patient using the foundation's proprietary discovery platform: massive parallel screening of thousands of mRNA sites is coupled with machine-learning algorithms to optimize drug-like properties, and six distinct molecular mechanisms (RNase H1-mediated degradation, splicing modulation, nonsense-mediated decay inhibition, uORF targeting, polyadenylation redirection, and translation inhibition) are available to either up- or down-regulate protein expression. Organ-specific delivery expertise covers the central nervous system, liver, kidney, and eye via subcutaneous, intravitreal, and intrathecal routes. Quality and pre-clinical work is supported by Charles River Laboratories; manufacturing by Nitto Avecia, ChemGenes, Hongene and Cytiva; sequencing and diagnostics by Illumina, GeneDx, IDT, Children's Mercy Kansas City and (proposed) PacBio; and clinical operations by Parexel. The foundation reports >90% clinically significant benefit rates across evaluable patients with no ASO-related serious adverse events.

The business model is philanthropic rather than commercial. Revenue is generated from charitable donations and directed gifts from pharmaceutical and biotech partners (Biogen as founding donor, Alexion, Alnylam, Takeda, Ultragenyx, Servier, GondolaBio), foundations (Conrad Prebys, Solve FSHD, Wolverine, J. Wood Capital), federal and state grants (including NIH support via the Undiagnosed Diseases Network), and milestone/royalty arrangements from commercial partnerships. Average per-treatment cost is approximately $1.2 million, largely subsidized through in-kind manufacturing and reagent donations. Go-to-market is community-led: research physicians at tertiary care centers submit applications on behalf of genetically confirmed patients via the foundation's Application for Treatment Portal, and patients engage through the Patient Empowerment Program, an annual Nano-rare Patient Colloquium (hosted by Biogen), and the "Lessons in Antisense" podcast. The foundation is governed by a Board of Directors chaired by Crooke, employs 31 people, and operates from San Diego with a second laboratory in El Cajon.

Short descriptiontext

n-Lorem Foundation is a 501(c)(3) nonprofit that designs and provides personalized experimental antisense oligonucleotide (ASO) medicines, free for life, to nano-rare disease patients (1-30 patients worldwide per mutation). Founded in 2020 by Ionis Pharmaceuticals founder Stanley Crooke, it has treated 50+ patients with 260+ cumulative doses.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense oligonucleotide therapy, rare disease therapeutics, personalized genomic medicine, nonprofit biotech foundation, individualized ASO medicines
Industry4 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Personalized Genomic Medicine
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Charitable Donations and Philanthropy
TypeOthers
Description

Primary funding source including donations from pharmaceutical companies (Biogen, Alexion, Alnylam, Takeda, Ultragenyx, Servier), biotechnology companies, foundations (Conrad Prebys Foundation, SolveFSHD, Wolverine Foundation), and individual donors. The organization received over $30 million in cash and significant in-kind donations within the first 18 months. In 2025, charitable contributions grew meaningfully with several major donors added.

nlorem.org
2Federal and State Grants
TypeGrants Donations
Description

Funding from government sources including NIH support through the Undiagnosed Diseases Network and other grant programs.

nlorem.org
3Directed Donations
TypeOthers
Description

Support for specific gene or mutation research programs. For each directed donation, n-Lorem requests an additional donation to the general fund for treating all patients. Directed donors include industry partners funding specific ASO programs.

nlorem.org
4Commercial Partnerships - Milestones and Royalties
TypeLicensing Royalties
Description

Relationships with commercial partners generate funding through milestone payments and potential royalties. These transactions are subject to strict criteria ensuring consistency with n-Lorem's mission. In 2025, milestones were achieved from existing partnerships.

nlorem.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales, Others
Pricing details1 tier
1Free treatment for all qualified nano-rare patients
ModelOtherBilling cadenceOthers
Notes

All treatments are provided at no cost to patients. n-Lorem is a qualified 501(c)(3) tax-exempt organization (EIN: 84-3288113). As a non-profit, it is the policy of n-Lorem to not pay indirect costs. The cost to develop and provide each personalized ASO treatment averages approximately $1.2 million per patient.

nlorem.org
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

n-Lorem Foundation develops and provides personalized experimental antisense oligonucleotide (ASO) medicines, for free for life, to patients with nano-rare genetic diseases (1-30 patients worldwide with the same mutation). Each treatment is designed for an individual patient's unique single-gene mutation affecting the central nervous system, liver, kidney, or eye, leveraging 30+ years of ASO technology expertise developed at Ionis Pharmaceuticals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Greater than 90% success rate with clinically significant benefit achieved in nearly all evaluable patients
+5 more records
Product overview1 text field

n-Lorem Foundation operates as a single, unified service offering centered on providing personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare patients. The core offering is the ASO Technology Platform, which enables the discovery and development of individualized ASO medicines for patients with single-gene mutations affecting 1-30 patients worldwide. Supporting services include a Patient Application Portal for treatment evaluation, an annual Nano-Rare Patient Colloquium for community engagement, and a Patient Empowerment Program providing education and support resources. All treatments are provided at no cost to patients for life, representing a charitable nonprofit model rather than a commercial pharmaceutical product portfolio.

Product and service1 record
1Personalized Experimental ASO Medicines
CategoryPersonalized Experimental Therapeutics
Description

Individualized antisense oligonucleotide (ASO) medicines developed for each nano-rare patient with a confirmed single-gene mutation affecting the central nervous system, liver, kidney, or eye. Each ASO is a short, modified DNA strand designed to bind precise RNA target sites and modulate disease-causing protein expression via mechanisms such as RNase H1-mediated degradation, splicing modulation, nonsense-mediated decay inhibition, uORF targeting, polyadenylation redirection, or translation inhibition. Provided free for life to qualifying patients under Research INDs.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Multi-target research collaboration to develop antisense oligonucleotide (ASO) therapeutic approaches for rare neurodevelopmental disorders. n-Lorem leverages its ASO technology platform to engineer preclinical candidates, which Servier advances into clinical development. Partnership addresses rare neurological diseases including refractory epilepsy, genetically-driven autism spectrum disorders, and leukodystrophies. Supports Servier's 2030 ambition for rare neurological diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

Founding member of One to Millions initiative - a global public-private initiative to enable scalable development of advanced individualized therapies such as ASOs, gene therapies, and RNA-based treatments. Initiative creates standardized development pathways, integrates post-authorization evidence generation, and reduces unnecessary animal testing. Also includes Mila's Miracle Foundation and N=1 Collaborative.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Strategic collaboration to expand access to n-Lorem's individualized ASO therapies in Europe. Initial focus on treating a small number of patients in Switzerland as proof-of-concept before expanding across the EU. Addresses regulatory, operational, and diagnostic barriers limiting access to personalized genetic medicines outside the United States. First treatments anticipated within the first year.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-12
Description

Proposed strategic collaboration to leverage PacBio's long-read whole-genome sequencing technology for developing individualized ASO therapies for ultra-rare genetic diseases. PacBio would donate sequencing reagents and provide scientific expertise for long-read genome analysis to reduce sequential testing, accelerate target validation, and improve ASO design confidence. Remains subject to negotiation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to expand technology access to RNAi therapeutics for patients with nano-rare diseases where an RNAi directed approach would be most useful. Alnylam's vision is to harness potential of RNAi therapeutics for limited treatment options.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Clinical partner providing clinical operations, real-world data solutions, medical and regulatory expertise and innovative clinical research tools. One of world's leading global clinical research organizations. Helps manage the complex database and natural history studies for n-Lorem's patient programs.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Provides support for substantial amount of pre-clinical toxicity studies and data collection to support regulatory filing. Global provider of drug discovery and development services.

Strategic tierCoreTypeTechnology or Integration
Description

Leading independent children's health organization providing genomic sequencing support. Dedicated to holistic care, translational research, breakthrough innovation, and educating next generation of caregivers.

Strategic tierCoreTypeTechnology or Integration
Description

Helps understand the genetic cause of nano-rare mutations. Leader in delivering clinical genomic answers to patients, families and healthcare providers.

Strategic tierCoreTypeTechnology or Integration
Description

Supports nano-rare patients by sequencing patient genomes to identify and understand each patient's unique mutation. Goal is to apply innovative technologies to analysis of genetic variation and function.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Provides significant manufacturing support for n-Lorem and patients. Helps offset costs of developing personalized experimental ASO medicines.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Donor and partner providing manufacturing support through contributions of active pharmaceutical ingredients (API) and drug product for individualized ASO medicines. Over 25 years of oligonucleotide innovation through development and production.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-profit organization envisioning world where everyone with ALS lives. Partnership supports ALS patient characterization and ASO development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Initiative aligning Columbia University and n-Lorem to support characterization of nano-rare ALS patients and discovery and development of personalized experimental ASO medicines for these patients. Founded by Dr. Neil Shneider.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Non-profit advancing research and discovering novel therapeutic approaches for neurodevelopmental disease caused by genetic variations in MAPK8IP3 gene.

Strategic tierCoreTypeTechnology or Integration
Description

NIH-funded research study bringing together clinical and research experts to solve most challenging medical mysteries using advanced technologies. Provides access to appropriately characterized patients and investigators.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical-stage biotechnology company dedicated to developing novel medicines for patients living with genetic diseases. Partner in discovering novel ASO medicines for patients not currently served by available treatment options.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nonprofit foundation created to develop a personalized antisense oligonucleotide treatment for Mila Makovec, a child with Batten disease. Like n-Lorem, it pioneered the individualized ASO concept for a single patient and now co-leads the One to Millions initiative with n-Lorem. Directly comparable as the original N-of-1 ASO foundation.

TypeDirect peer
Description

Organization focused on advancing individualized therapeutics for patients with rare genetic diseases. Co-founding member of the One to Millions initiative alongside n-Lorem and Mila's Miracle. Directly comparable mission and approach to enabling individualized medicine development.

TypeDirect peer
Description

Swiss nonprofit foundation partnering with n-Lorem (announced January 2026) to expand individualized ASO therapies into Europe, initially Switzerland. Operates a comparable nonprofit model focused on developing treatments for ultra-rare diseases that lack commercial paths.

TypeBroad incumbent
Description

The originator of ASO technology where founder Stanley Crooke led creation of the platform for 30+ years. Commercial ASO developer with a broad pipeline across rare and common diseases. Comparable because n-Lorem's technology platform is a direct spinoff of Ionis's ASO expertise and several senior staff are Ionis alumni.

TypeBroad incumbent
Description

Leading global biotechnology company that is n-Lorem's founding donor and host of the annual Nano-rare Patient Colloquium. Licensee of ASO technology from Ionis with multiple commercial ASO products (e.g., Spinraza, Tofersen). Comparable because Biogen supports n-Lorem's mission while also operating in the broader ASO and rare disease neurology space.

TypeBroad incumbent
Description

Pioneer of RNAi therapeutics and n-Lorem partner. Alnylam partners with n-Lorem to expand technology access to RNAi for nano-rare patients. Comparable because both focus on RNA-targeted precision medicines for rare diseases, and Alnylam's commercial platform represents what an industrialized version of n-Lorem's individualized approach could become.

TypeEmerging player
Description

Clinical-stage biotechnology company developing antisense oligonucleotide medicines for severe genetic diseases using TANGO technology for RNA-targeted augmentation. Comparable as an emerging commercial ASO developer focused on rare diseases, representing a more commercially-oriented version of n-Lorem's ASO mission.

TypeBroad incumbent
Description

Commercial-stage gene therapy company focused on rare neuromuscular diseases. While operating in a different modality (gene therapy vs. ASO), Sarepta is comparable as a leading rare disease therapeutics company that has built infrastructure and regulatory pathways n-Lorem benefits from and aspires to enable for nano-rare populations.

TypeEmerging player
Description

Clinical-stage biotechnology company developing RNA-editing therapeutics (Axiomer platform) for rare genetic diseases. Comparable as an emerging RNA-targeted rare disease player; their platform technology could be an alternative or complement to n-Lorem's ASO approach for certain nano-rare mutations.

TypeOthers
Description

Public-private partnership that launched the One to Millions initiative with n-Lorem as a founding member. Not a direct peer but a key ecosystem enabler: C-Path develops regulatory tools and standardized pathways that benefit n-Lorem's individualized therapy programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

n-Lorem Foundation

Personalized Genomic Medicinenlorem.org

n-Lorem Foundation is a 501(c)(3) nonprofit that designs and provides personalized experimental antisense oligonucleotide (ASO) medicines, free for life, to nano-rare disease patients (1-30 patients worldwide per mutation). Founded in 2020 by Ionis Pharmaceuticals founder Stanley Crooke, it has treated 50+ patients with 260+ cumulative doses.

What n-Lorem Foundation does

n-Lorem Foundation is a 501(c)(3) nonprofit founded in January 2020 by Dr. Stanley Crooke — the founder of Ionis Pharmaceuticals and creator of antisense oligonucleotide (ASO) technology — to develop and provide personalized experimental ASO medicines to nano-rare disease patients (defined as 1-30 patients worldwide sharing a single pathogenic mutation) for free, for life. The foundation is the only organization worldwide operating at scale on individualized ASOs, with 50+ patients treated, 260+ doses administered, 40+ INDs filed across five FDA divisions plus one CTA with Health Canada, and over 45 patient-years of cumulative safety experience as of April 2026.

The core product is a personalized experimental ASO medicine engineered per patient using the foundation's proprietary discovery platform: massive parallel screening of thousands of mRNA sites is coupled with machine-learning algorithms to optimize drug-like properties, and six distinct molecular mechanisms (RNase H1-mediated degradation, splicing modulation, nonsense-mediated decay inhibition, uORF targeting, polyadenylation redirection, and translation inhibition) are available to either up- or down-regulate protein expression. Organ-specific delivery expertise covers the central nervous system, liver, kidney, and eye via subcutaneous, intravitreal, and intrathecal routes. Quality and pre-clinical work is supported by Charles River Laboratories; manufacturing by Nitto Avecia, ChemGenes, Hongene and Cytiva; sequencing and diagnostics by Illumina, GeneDx, IDT, Children's Mercy Kansas City and (proposed) PacBio; and clinical operations by Parexel. The foundation reports >90% clinically significant benefit rates across evaluable patients with no ASO-related serious adverse events.

The business model is philanthropic rather than commercial. Revenue is generated from charitable donations and directed gifts from pharmaceutical and biotech partners (Biogen as founding donor, Alexion, Alnylam, Takeda, Ultragenyx, Servier, GondolaBio), foundations (Conrad Prebys, Solve FSHD, Wolverine, J. Wood Capital), federal and state grants (including NIH support via the Undiagnosed Diseases Network), and milestone/royalty arrangements from commercial partnerships. Average per-treatment cost is approximately $1.2 million, largely subsidized through in-kind manufacturing and reagent donations. Go-to-market is community-led: research physicians at tertiary care centers submit applications on behalf of genetically confirmed patients via the foundation's Application for Treatment Portal, and patients engage through the Patient Empowerment Program, an annual Nano-rare Patient Colloquium (hosted by Biogen), and the "Lessons in Antisense" podcast. The foundation is governed by a Board of Directors chaired by Crooke, employs 31 people, and operates from San Diego with a second laboratory in El Cajon.

n-Lorem Foundation firmographics

Firmographics
Name
n-Lorem Foundation
Legal name
n-Lorem Foundation
Website
https://nlorem.org
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
n-Lorem Foundation is a 501(c)(3) nonprofit that designs and provides personalized experimental antisense oligonucleotide (ASO) medicines, free for life, to nano-rare disease patients (1-30 patients worldwide per mutation). Founded in 2020 by Ionis Pharmaceuticals founder Stanley Crooke, it has treated 50+ patients with 260+ cumulative doses.
Ownership category
akta.pro rank

n-Lorem Foundation industry classification

Industry
Product category
Personalized Genomic Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Antisense oligonucleotide therapy
  • Rare disease therapeutics
  • Personalized genomic medicine
  • Nonprofit biotech foundation
  • Individualized ASO medicines

Where n-Lorem Foundation is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices2 records

Markets served

n-Lorem Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

  1. Charitable Donations and Philanthropy: Primary funding source including donations from pharmaceutical companies (Biogen, Alexion, Alnylam, Takeda, Ultragenyx, Servier), biotechnology companies, foundations (Conrad Prebys Foundation, SolveFSHD, Wolverine Foundation), and individual donors. The organization received over $30 million in cash and significant in-kind donations within the first 18 months. In 2025, charitable contributions grew meaningfully with several major donors added.
  2. Federal and State Grants: Funding from government sources including NIH support through the Undiagnosed Diseases Network and other grant programs.
  3. Directed Donations: Support for specific gene or mutation research programs. For each directed donation, n-Lorem requests an additional donation to the general fund for treating all patients. Directed donors include industry partners funding specific ASO programs.
  4. Commercial Partnerships - Milestones and Royalties: Relationships with commercial partners generate funding through milestone payments and potential royalties. These transactions are subject to strict criteria ensuring consistency with n-Lorem's mission. In 2025, milestones were achieved from existing partnerships.

Pricing tiers

ModelBillingPrice
OtherOthersFree treatment for all qualified nano-rare patients

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

n-Lorem Foundation product offering

Product offering

Core offering

n-Lorem Foundation develops and provides personalized experimental antisense oligonucleotide (ASO) medicines, for free for life, to patients with nano-rare genetic diseases (1-30 patients worldwide with the same mutation). Each treatment is designed for an individual patient's unique single-gene mutation affecting the central nervous system, liver, kidney, or eye, leveraging 30+ years of ASO technology expertise developed at Ionis Pharmaceuticals.

Product overview

n-Lorem Foundation operates as a single, unified service offering centered on providing personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare patients. The core offering is the ASO Technology Platform, which enables the discovery and development of individualized ASO medicines for patients with single-gene mutations affecting 1-30 patients worldwide. Supporting services include a Patient Application Portal for treatment evaluation, an annual Nano-Rare Patient Colloquium for community engagement, and a Patient Empowerment Program providing education and support resources. All treatments are provided at no cost to patients for life, representing a charitable nonprofit model rather than a commercial pharmaceutical product portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Personalized Experimental ASO Medicines Individualized antisense oligonucleotide (ASO) medicines developed for each nano-rare patient with a confirmed single-gene mutation affecting the central nervous system, liver, kidney, or eye. Each ASO is a short, modified DNA strand designed to bind precise RNA target sites and modulate disease-causing protein expression via mechanisms such as RNase H1-mediated degradation, splicing modulation, nonsense-mediated decay inhibition, uORF targeting, polyadenylation redirection, or translation inhibition. Provided free for life to qualifying patients under Research INDs.

Quantifiable outcome

  • Greater than 90% success rate with clinically significant benefit achieved in nearly all evaluable patients
  • +5 more outcomes

Companies that use n-Lorem Foundation

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

n-Lorem Foundation technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

n-Lorem Foundation partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core.

  • ServiercoreStrategic or Co-development Partner · 10 June 2026Multi-target research collaboration to develop antisense oligonucleotide (ASO) therapeutic approaches for rare neurodevelopmental disorders. n-Lorem leverages its ASO technology platform to engineer preclinical candidates, which Servier advances into clinical development. Partnership addresses rare neurological diseases including refractory epilepsy, genetically-driven autism spectrum disorders, and leukodystrophies. Supports Servier's 2030 ambition for rare neurological diseases.
  • Critical Path Institute (C-Path)coreStrategic or Co-development Partner · 26 March 2026Founding member of One to Millions initiative - a global public-private initiative to enable scalable development of advanced individualized therapies such as ASOs, gene therapies, and RNA-based treatments. Initiative creates standardized development pathways, integrates post-authorization evidence generation, and reduces unnecessary animal testing. Also includes Mila's Miracle Foundation and N=1 Collaborative.
  • EspeRare FoundationcoreStrategic or Co-development Partner · 13 January 2026Strategic collaboration to expand access to n-Lorem's individualized ASO therapies in Europe. Initial focus on treating a small number of patients in Switzerland as proof-of-concept before expanding across the EU. Addresses regulatory, operational, and diagnostic barriers limiting access to personalized genetic medicines outside the United States. First treatments anticipated within the first year.
  • Pacific Biosciences (PacBio)coreTechnology or Integration · 12 January 2026Proposed strategic collaboration to leverage PacBio's long-read whole-genome sequencing technology for developing individualized ASO therapies for ultra-rare genetic diseases. PacBio would donate sequencing reagents and provide scientific expertise for long-read genome analysis to reduce sequential testing, accelerate target validation, and improve ASO design confidence. Remains subject to negotiation.
  • AlnylamcoreStrategic or Co-development PartnerPartnership to expand technology access to RNAi therapeutics for patients with nano-rare diseases where an RNAi directed approach would be most useful. Alnylam's vision is to harness potential of RNAi therapeutics for limited treatment options.
  • ParexelcoreImplementation/ SI/ Consulting PartnerClinical partner providing clinical operations, real-world data solutions, medical and regulatory expertise and innovative clinical research tools. One of world's leading global clinical research organizations. Helps manage the complex database and natural history studies for n-Lorem's patient programs.
  • Charles River LaboratoriescoreImplementation/ SI/ Consulting PartnerProvides support for substantial amount of pre-clinical toxicity studies and data collection to support regulatory filing. Global provider of drug discovery and development services.
  • Children's Mercy Kansas CitycoreTechnology or IntegrationLeading independent children's health organization providing genomic sequencing support. Dedicated to holistic care, translational research, breakthrough innovation, and educating next generation of caregivers.
  • GeneDxcoreTechnology or IntegrationHelps understand the genetic cause of nano-rare mutations. Leader in delivering clinical genomic answers to patients, families and healthcare providers.
  • IlluminacoreTechnology or IntegrationSupports nano-rare patients by sequencing patient genomes to identify and understand each patient's unique mutation. Goal is to apply innovative technologies to analysis of genetic variation and function.
  • ChemGenes CorporationcoreImplementation/ SI/ Consulting PartnerProvides significant manufacturing support for n-Lorem and patients. Helps offset costs of developing personalized experimental ASO medicines.
  • Nitto AveciacoreImplementation/ SI/ Consulting PartnerDonor and partner providing manufacturing support through contributions of active pharmaceutical ingredients (API) and drug product for individualized ASO medicines. Over 25 years of oligonucleotide innovation through development and production.
  • Target ALScoreStrategic or Co-development PartnerNon-profit organization envisioning world where everyone with ALS lives. Partnership supports ALS patient characterization and ASO development.
  • Silence ALScoreStrategic or Co-development PartnerInitiative aligning Columbia University and n-Lorem to support characterization of nano-rare ALS patients and discovery and development of personalized experimental ASO medicines for these patients. Founded by Dr. Neil Shneider.
  • Wolverine FoundationcoreStrategic or Co-development PartnerNon-profit advancing research and discovering novel therapeutic approaches for neurodevelopmental disease caused by genetic variations in MAPK8IP3 gene.
  • Undiagnosed Diseases Network (UDN)coreTechnology or IntegrationNIH-funded research study bringing together clinical and research experts to solve most challenging medical mysteries using advanced technologies. Provides access to appropriately characterized patients and investigators.
  • GondolaBiocoreStrategic or Co-development PartnerClinical-stage biotechnology company dedicated to developing novel medicines for patients living with genetic diseases. Partner in discovering novel ASO medicines for patients not currently served by available treatment options.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

n-Lorem Foundation competitors and assessment

Company assessment

Direct peers

  • Mila's Miracle Foundation: Nonprofit foundation created to develop a personalized antisense oligonucleotide treatment for Mila Makovec, a child with Batten disease. Like n-Lorem, it pioneered the individualized ASO concept for a single patient and now co-leads the One to Millions initiative with n-Lorem. Directly comparable as the original N-of-1 ASO foundation.
  • N=1 Collaborative: Organization focused on advancing individualized therapeutics for patients with rare genetic diseases. Co-founding member of the One to Millions initiative alongside n-Lorem and Mila's Miracle. Directly comparable mission and approach to enabling individualized medicine development.
  • EspeRare Foundation: Swiss nonprofit foundation partnering with n-Lorem (announced January 2026) to expand individualized ASO therapies into Europe, initially Switzerland. Operates a comparable nonprofit model focused on developing treatments for ultra-rare diseases that lack commercial paths.

Broad incumbents

  • Ionis Pharmaceuticals: The originator of ASO technology where founder Stanley Crooke led creation of the platform for 30+ years. Commercial ASO developer with a broad pipeline across rare and common diseases. Comparable because n-Lorem's technology platform is a direct spinoff of Ionis's ASO expertise and several senior staff are Ionis alumni.
  • Biogen: Leading global biotechnology company that is n-Lorem's founding donor and host of the annual Nano-rare Patient Colloquium. Licensee of ASO technology from Ionis with multiple commercial ASO products (e.g., Spinraza, Tofersen). Comparable because Biogen supports n-Lorem's mission while also operating in the broader ASO and rare disease neurology space.
  • Alnylam Pharmaceuticals: Pioneer of RNAi therapeutics and n-Lorem partner. Alnylam partners with n-Lorem to expand technology access to RNAi for nano-rare patients. Comparable because both focus on RNA-targeted precision medicines for rare diseases, and Alnylam's commercial platform represents what an industrialized version of n-Lorem's individualized approach could become.
  • Sarepta Therapeutics: Commercial-stage gene therapy company focused on rare neuromuscular diseases. While operating in a different modality (gene therapy vs. ASO), Sarepta is comparable as a leading rare disease therapeutics company that has built infrastructure and regulatory pathways n-Lorem benefits from and aspires to enable for nano-rare populations.

Emerging players

  • Stoke Therapeutics: Clinical-stage biotechnology company developing antisense oligonucleotide medicines for severe genetic diseases using TANGO technology for RNA-targeted augmentation. Comparable as an emerging commercial ASO developer focused on rare diseases, representing a more commercially-oriented version of n-Lorem's ASO mission.
  • ProQR Therapeutics: Clinical-stage biotechnology company developing RNA-editing therapeutics (Axiomer platform) for rare genetic diseases. Comparable as an emerging RNA-targeted rare disease player; their platform technology could be an alternative or complement to n-Lorem's ASO approach for certain nano-rare mutations.

Others

  • Critical Path Institute (C-Path): Public-private partnership that launched the One to Millions initiative with n-Lorem as a founding member. Not a direct peer but a key ecosystem enabler: C-Path develops regulatory tools and standardized pathways that benefit n-Lorem's individualized therapy programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks5 records

Key highlights7 records

Customer concentration

n-Lorem Foundation social profiles

Digital presence

n-Lorem Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

n-Lorem Foundation leadership team

Management profile

Number of profiles

Profiles1 record

n-Lorem Foundation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

n-Lorem Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about n-Lorem Foundation

What does n-Lorem Foundation do?

n-Lorem Foundation develops and provides personalized experimental antisense oligonucleotide (ASO) medicines, for free for life, to patients with nano-rare genetic diseases (1-30 patients worldwide with the same mutation). Each treatment is designed for an individual patient's unique single-gene mutation affecting the central nervous system, liver, kidney, or eye, leveraging 30+ years of ASO technology expertise developed at Ionis Pharmaceuticals.

Is n-Lorem Foundation a public or private company?

n-Lorem Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was n-Lorem Foundation founded?

n-Lorem Foundation was founded in 2020. It employs 11 to 50 people.

Where is n-Lorem Foundation based?

n-Lorem Foundation is headquartered in Carlsbad, United States, in the North America region.

How does n-Lorem Foundation make money?

Four revenue lines are on record. Charitable Donations and Philanthropy is the primary driver. The others are federal and State Grants, directed Donations and commercial Partnerships - Milestones and Royalties.

Who are n-Lorem Foundation's main competitors?

Direct peers on record are Mila's Miracle Foundation, N=1 Collaborative and EspeRare Foundation. Broad incumbents are Ionis Pharmaceuticals, Biogen, Alnylam Pharmaceuticals and Sarepta Therapeutics. Emerging players are Stoke Therapeutics and ProQR Therapeutics. Critical Path Institute (C-Path) is listed as an others.

Does n-Lorem Foundation have an API?

No public API is recorded for n-Lorem Foundation.

What industry is n-Lorem Foundation in?

n-Lorem Foundation's product category is Personalized Genomic Medicine. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
San Diego Business Journaln-Lorem Foundation Giving Ultra-rare Disease Patients a Chancen-Lorem Foundation and BioMarin announced a partnership to develop a potential treatment for ReNU syndrome using antisense oligonucleotide technology. The condition affects about 75% of cases via RNU4-2 mutations, with a global population of roughly 100,000. Treatment could begin by end of year or early next year.YahooBioMarin (BMRN) Stock May Be Above Fair Value After ReNU Therapy DealBioMarin Pharmaceutical trades at a P/E ratio of 44.2x, significantly above both its industry average of 17.6x and peer group average of 21.2x, suggesting the stock may be overvalued relative to comparable companies. The Fair Ratio model indicates a P/E of approximately 27.6x would be more reasonable, pointing to investors paying a steep premium. A new collaboration with the n-Lorem Foundation on an antisense therapy for ReNU syndrome could support sentiment if the program progresses, though early-stage execution risks remain.Pharmaceutical TechnologyBioMarin, n-Lorem partner on early research for ReNU syndrome therapyBioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global license agreement to develop an investigational antisense oligonucleotide therapy for ReNU syndrome, a rare neurodevelopmental disorder caused by variants in the RNU4-2 gene that was recognized as a distinct genetic disorder in 2024. The agreement aims to address an estimated 75% of ReNU syndrome cases, with BioMarin leading development for broader patient use while n-Lorem continues preparatory enrollment for individualized clinical trials. The therapy represents a potential first treatment option addressing the underlying genetic cause of the disease for which there are currently no approved medicines.Seeking AlphaBioMarin, n-Lorem Foundation to collaborate on ReNU syndrome treatmentBioMarin Pharmaceutical and the n-Lorem Foundation have entered an early research collaboration to develop an antisense oligonucleotide therapy for ReNU syndrome, a rare neurodevelopmental genetic disorder. The therapy candidate will target the n.64_65insT variant of the RNU4-2 gene, which is believed to be responsible for approximately 75% of ReNU cases. Both parties will conduct preclinical studies and jointly decide which candidate to advance into clinical development.Investing.comBioMarin partners with n-Lorem to develop ReNU syndrome treatment By Investing.comBioMarin Pharmaceutical Inc. and the n-Lorem Foundation announced a strategic collaboration and global exclusive license agreement to develop an antisense oligonucleotide medicine targeting ReNU syndrome, a rare genetic neurodevelopmental condition affecting an estimated 100,000 people worldwide. The collaboration will advance an investigational ASO candidate targeting the RNU4-2 variant, which accounts for approximately 75% of ReNU syndrome cases, with both companies conducting preclinical studies to select a lead candidate for clinical development. No medicines are currently approved for ReNU syndrome, which was discovered in 2024 and is projected to become one of the leading monogenetic causes of developmental delay and impairment.AInvestBiomarin Pharmaceutical and N-Lorem announce global exclusive license to develop ASO medicine for Renu syndromeBiomarin Pharmaceutical and N-Lorem have announced a global exclusive license agreement to develop an antisense oligonucleotide medicine for Renu syndrome, a rare medical condition.PR NewswireBioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU SyndromeBioMarin Pharmaceutical Inc. and n-Lorem Foundation announced a strategic collaboration and global exclusive license agreement to develop a first-in-disease antisense oligonucleotide medicine for ReNU syndrome, a rare neurodevelopmental genetic condition. ReNU syndrome was discovered in 2024 and is estimated to affect approximately 100,000 people globally, with no approved medicines currently addressing its underlying genetic cause. The companies will conduct preclinical studies to select a lead candidate, with BioMarin leading development for the broader patient population while n-Lorem had initially initiated individualized clinical trials for a smaller cohort.Stock TitanBioMarin, n-Lorem ReNU Deal Targets About 75% of CasesBioMarin Pharmaceutical Inc. and n-Lorem Foundation announced a strategic collaboration and global exclusive license agreement to develop a first-in-disease antisense oligonucleotide medicine for ReNU syndrome, targeting the RNU4-2 variant estimated to account for approximately 75% of cases. ReNU syndrome was first identified in 2024 and currently has no approved medicines addressing its underlying genetic cause. Under the agreement, BioMarin will lead development for the broader ReNU syndrome community while both parties conduct preclinical studies to select a lead candidate for clinical trials.FinancialContent Business PageImpressive Benefits and an Excellent Safety and Tolerability Profiles in Two Severely Affected Patients With Mutations in a Vital Sodium Channel (SCN2A) Treated With Bespoke ASOs Reported in Nature Men-Lorem Foundation announced publication in Nature Medicine of results from two first-in-human clinical trials of personalized allele-selective antisense oligonucleotide (ASO) medicines for patients with pathogenic SCN2A gene mutations. Both patients demonstrated excellent safety and tolerability profiles with no ASO-related adverse events over more than two years of treatment, while experiencing significant reductions in seizures, motor dysfunction improvements, and developmental milestone achievements including independent walking. The findings represent a significant advancement in ASO therapeutics for nano-rare genetic disorders affecting 1-30 patients worldwide.AijournServier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disordersServier and n-Lorem Foundation announced a multi-target research collaboration to develop antisense oligonucleotide (ASO) therapeutic approaches for rare neurodevelopmental disorders. Under the agreement, n-Lorem will leverage its ASO technology platform to engineer preclinical candidates, which Servier will advance into clinical development, with the aim of extending precision genetic medicine to patients with limited treatment options. The partnership supports Servier's 2030 ambition to develop innovative treatments for rare neurological diseases including refractory epilepsy, genetically-driven autism spectrum disorders, and leukodystrophies.